

David W Boulton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2714938/publications.pdf>

Version: 2024-02-01

94
papers

3,706
citations

136740

32
h-index

138251

58
g-index

94
all docs

94
docs citations

94
times ranked

3829
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 541-554. | 1.0 | 2 |
| 2 | Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1942-1946. | 1.1 | 8 |
| 3 | Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Impact of Chronic Kidney Disease on CYP3A4-Mediated Metabolism of Saxagliptin. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1018-1029. | 1.0 | 6 |
| 4 | Relationship of Dapagliflozin With Serum Sodium. <i>JACC: Heart Failure</i> , 2022, 10, 306-318. | 1.9 | 10 |
| 5 | Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1227-1235. | 1.0 | 6 |
| 6 | MO364: Population Pharmacodynamic Dose-Response Analysis of Serum Potassium Following Dosing With Sodium Zirconium Cyclosilicate. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, . | 0.4 | 0 |
| 7 | Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 636-648. | 1.0 | 9 |
| 8 | Evaluation of the Pharmacokinetics and Exposure-Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease. <i>Clinical Pharmacokinetics</i> , 2021, 60, 517-525. | 1.6 | 6 |
| 9 | Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1101-1110. | 2.2 | 4 |
| 10 | Evolving drug regulatory landscape in China: A clinical pharmacology perspective. <i>Clinical and Translational Science</i> , 2021, 14, 1222-1230. | 1.5 | 11 |
| 11 | Model-Informed Pediatric Dose Selection for Dapagliflozin by Incorporating Developmental Changes. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2021, 10, 108-118. | 1.3 | 11 |
| 12 | A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 991-1000. | 2.2 | 5 |
| 13 | Effects of sodium zirconium cyclosilicate on sodium and potassium excretion in healthy adults: a Phase 1 study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1924-1931. | 1.4 | 8 |
| 14 | Evaluation of potential drug interactions with sodium zirconium cyclosilicate: a single-center, open-label, one sequence crossover study in healthy adults. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1808-1816. | 1.4 | 1 |
| 15 | Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 798-806. | 2.2 | 11 |
| 16 | A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications. <i>Clinical Pharmacokinetics</i> , 2020, 59, 447-462. | 1.6 | 50 |
| 17 | Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. <i>Circulation</i> , 2020, 142, 1040-1054. | 1.6 | 128 |
| 18 | Renal Effects of Dapagliflozin in People with and without Diabetes with Moderate or Severe Renal Dysfunction: Prospective Modeling of an Ongoing Clinical Trial. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 76-91. | 1.3 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A <i>post hoc</i> analysis of the EXSCEL trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2493-2498. | 2.2 | 26 |
| 20 | Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1353. | 3.8 | 340 |
| 21 | Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 222-229. | 1.3 | 19 |
| 22 | Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2684-2693. | 2.2 | 28 |
| 23 | Effects of the sodium-glucose cotransporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2667-2673. | 2.2 | 73 |
| 24 | Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects. <i>Clinical Therapeutics</i> , 2019, 41, 1545-1563. | 1.1 | 5 |
| 25 | Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 138. | 2.7 | 48 |
| 26 | Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 380-395. | 1.3 | 33 |
| 27 | Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1820-1828. | 1.1 | 10 |
| 28 | Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1381-1387. | 2.2 | 6 |
| 29 | Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 829-836. | 2.2 | 6 |
| 30 | Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL. <i>Diabetes Care</i> , 2019, 42, 318-326. | 4.3 | 23 |
| 31 | Pharmacokinetic Interaction Study Between Saxagliptin and Omeprazole, Famotidine, or Magnesium and Aluminum Hydroxides Plus Simethicone in Healthy Subjects: An Open-Label Randomized Crossover Study. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 549-558. | 0.8 | 3 |
| 32 | Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 876-882. | 2.2 | 18 |
| 33 | SGLT2 Inhibition Is Predicted to Reduce LV End Diastolic Pressure: A Mathematical Modeling Analysis. <i>FASEB Journal</i> , 2019, 33, 531.17. | 0.2 | 0 |
| 34 | Exenatide effects on gastric emptying rate and the glucose rate of appearance in plasma: a quantitative assessment using an integrative systems pharmacology model. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2034-2038. | 2.2 | 4 |
| 35 | Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 479-487. | 2.2 | 336 |
| 36 | Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 315, F1295-F1306. | 1.3 | 46 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor. <i>Clinical Pharmacokinetics</i> , 2017, 56, 11-24. | 1.6 | 37 |
| 38 | Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study. <i>Clinical Therapeutics</i> , 2016, 38, 1890-1899. | 1.1 | 6 |
| 39 | Bioequivalence and food effect of heat-stressed and non-heat-stressed dapagliflozin 2.5- and 10-mg tablets. <i>International Journal of Pharmaceutics</i> , 2016, 511, 288-295. | 2.6 | 4 |
| 40 | Model-Based Phase 3 Dose Selection for HIV-1 Attachment Inhibitor Prodrug BMS-663068 in HIV-1-Infected Patients: Population Pharmacokinetics/Pharmacodynamics of the Active Moiety, BMS-626529. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 2782-2789. | 1.4 | 18 |
| 41 | Fed and Fasted Single-dose Assessment of Bioequivalence of Dapagliflozin and Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. <i>Clinical Therapeutics</i> , 2016, 38, 99-109. | 1.1 | 11 |
| 42 | Bioequivalence of saxagliptin/dapagliflozin fixed-dose combination tablets compared with coadministration of the individual tablets to healthy subjects. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00201. | 1.1 | 11 |
| 43 | Selective Reaction Monitoring of Negative Electrospray Ionization Acetate Adduct Ions for the Bioanalysis of Dapagliflozin in Clinical Studies. <i>Analytical Chemistry</i> , 2015, 87, 3247-3254. | 3.2 | 26 |
| 44 | Bioequivalence, Food Effect, and Steady-State Assessment of Dapagliflozin/Metformin Extended-release Fixed-dose Combination Tablets Relative to Single-component Dapagliflozin and Metformin Extended-release Tablets in Healthy Subjects. <i>Clinical Therapeutics</i> , 2015, 37, 1517-1528. | 1.1 | 14 |
| 45 | Use of systems pharmacology modeling to elucidate the operating characteristics of SGLT1 and SGLT2 in renal glucose reabsorption in humans. <i>Frontiers in Pharmacology</i> , 2014, 5, 274. | 1.6 | 38 |
| 46 | Validation of 4 β -hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 1122-1134. | 1.1 | 73 |
| 47 | Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose Co-transporter Type 2. <i>Clinical Pharmacokinetics</i> , 2014, 53, 17-27. | 1.6 | 180 |
| 48 | Use of low-dose clinical pharmacodynamic and pharmacokinetic data to establish an occupational exposure limit for dapagliflozin, a potent inhibitor of the renal sodium glucose co-transporter 2. <i>Regulatory Toxicology and Pharmacology</i> , 2013, 67, 89-97. | 1.3 | 7 |
| 49 | Bioequivalence of Saxagliptin/Metformin Immediate Release (IR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin IR Tablets in Healthy Adult Subjects. <i>Clinical Drug Investigation</i> , 2013, 33, 365-374. | 1.1 | 13 |
| 50 | Simultaneous oral therapeutic and intravenous ¹⁴ C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 763-768. | 1.1 | 72 |
| 51 | The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 432-444. | 1.1 | 98 |
| 52 | Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3169-3176. | 4.3 | 233 |
| 53 | Targeting Renal Glucose Reabsorption for the Treatment of Type 2 Diabetes Mellitus Using the SGLT2 Inhibitor Dapagliflozin. <i>Postgraduate Medicine</i> , 2012, 124, 62-73. | 0.9 | 12 |
| 54 | A Pharmacometric Approach to Quantify the Impact of Chronic Kidney Disease and Hemodialysis on Systemic Drug Exposure: Application to Saxagliptin. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 126S-33S. | 1.0 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Characterization of the In Vitro and In Vivo Metabolism and Disposition and Cytochrome P450 Inhibition/Induction Profile of Saxagliptin in Human. <i>Drug Metabolism and Disposition</i> , 2012, 40, 1345-1356. | 1.7 | 41 |
| 56 | Biowaiver Approach for Biopharmaceutics Classification System Class 3 Compound Metformin Hydrochloride Using In Silico Modeling. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 1773-1782. | 1.6 | 40 |
| 57 | Lack of Pharmacokinetic Interactions Between Dapagliflozin and Simvastatin, Valsartan, Warfarin, or Digoxin. <i>Advances in Therapy</i> , 2012, 29, 163-177. | 1.3 | 50 |
| 58 | Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin. <i>Clinical Pharmacokinetics</i> , 2011, 50, 253-265. | 1.6 | 93 |
| 59 | Bioequivalence of Saxagliptin/Metformin Extended-Release (XR) Fixed-Dose Combination Tablets and Single-Component Saxagliptin and Metformin XR Tablets in Healthy Adult Subjects. <i>Clinical Drug Investigation</i> , 2011, 31, 619-630. | 1.1 | 19 |
| 60 | Two-way pharmacokinetic interaction studies between saxagliptin and cytochrome P450 substrates or inhibitors: simvastatin, diltiazem extended-release, and ketoconazole. <i>Clinical Pharmacology: Advances and Applications</i> , 2011, 3, 13. | 0.8 | 22 |
| 61 | Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 92-102. | 1.1 | 27 |
| 62 | The effects of age and gender on the pharmacokinetics and pharmacodynamics in healthy subjects of the plasminogen activator, lanoteplase. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 775-786. | 1.1 | 5 |
| 63 | Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study. <i>Clinical Therapeutics</i> , 2011, 33, 1798-1808. | 1.1 | 75 |
| 64 | Effect of a High-Fat Meal on the Pharmacokinetics of Saxagliptin in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 1211-1216. | 1.0 | 19 |
| 65 | Pharmacokinetics of the Dipeptidyl Peptidase 4 Inhibitor Saxagliptin in Rats, Dogs, and Monkeys and Clinical Projections. <i>Drug Metabolism and Disposition</i> , 2009, 37, 1164-1171. | 1.7 | 89 |
| 66 | A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. <i>Human Psychopharmacology</i> , 2009, 24, 145-152. | 0.7 | 18 |
| 67 | An Open-Label Study of Aripiprazole: Pharmacokinetics, Tolerability, and Effectiveness in Children and Adolescents with Conduct Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 431-439. | 0.7 | 42 |
| 68 | Pharmacokinetics and Tolerability of Intramuscular, Oral and Intravenous Aripiprazole in Healthy Subjects and in Patients with Schizophrenia. <i>Clinical Pharmacokinetics</i> , 2008, 47, 475-485. | 1.6 | 27 |
| 69 | Effects of Hepatic or Renal Impairment on the Pharmacokinetics of Aripiprazole. <i>Clinical Pharmacokinetics</i> , 2008, 47, 533-542. | 1.6 | 37 |
| 70 | Tolerability and Pharmacokinetics of Aripiprazole in Children and Adolescents With Psychiatric Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 441-446. | 0.7 | 56 |
| 71 | Pharmacokinetics of Aripiprazole and Concomitant Carbamazepine. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 279-283. | 0.7 | 47 |
| 72 | Preclinical Pharmacokinetics and Metabolism of BMS-214778, a Novel Melatonin Receptor Agonist. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 760-772. | 1.6 | 44 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Validation and application of a high-performance liquid chromatography/tandem mass spectrometry assay for sumatriptan in human plasma. <i>Biomedical Chromatography</i> , 2003, 17, 48-52. | 0.8 | 20 |
| 74 | One step purification of alpha1-acid glycoprotein from human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 784, 33-38. | 1.2 | 8 |
| 75 | Dietary levels of quinine in tonic water do not inhibit CYP2D6 in vivo. <i>Food and Chemical Toxicology</i> , 2003, 41, 1199-1201. | 1.8 | 16 |
| 76 | Great Expectations in Stereochemistry: Focus on Antidepressants. <i>CNS Spectrums</i> , 2002, 7, 28-33. | 0.7 | 17 |
| 77 | Differential Time Course of Cytochrome P450 2D6 Enzyme Inhibition by Fluoxetine, Sertraline, and Paroxetine in Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 169-173. | 0.7 | 70 |
| 78 | Hypotension and Bradycardia in a Healthy Volunteer following a Single 5 mg Dose of Olanzapine. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 104-106. | 1.0 | 25 |
| 79 | β ₂ -Agonist Eutomers. <i>Treatments in Respiratory Medicine</i> , 2002, 1, 305-311. | 1.4 | 7 |
| 80 | In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. <i>Life Sciences</i> , 2002, 71, 163-169. | 2.0 | 235 |
| 81 | Validation and application of a sensitive assay for butorphanol in human plasma by high-performance liquid chromatography with tandem mass spectrometry detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002, 775, 57-62. | 1.2 | 5 |
| 82 | The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2002, 71, 30-38. | 2.3 | 36 |
| 83 | The Pharmacokinetics of Levosalbutamol. <i>Clinical Pharmacokinetics</i> , 2001, 40, 23-40. | 1.6 | 64 |
| 84 | A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 350-354. | 1.1 | 20 |
| 85 | In vitro metabolism of mirtazapine enantiomers by human cytochrome P450 enzymes. <i>Human Psychopharmacology</i> , 2001, 16, 541-544. | 0.7 | 44 |
| 86 | Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 48-57. | 2.3 | 65 |
| 87 | Single-Dose Pharmacokinetics of Methylphenidate in CYP2D6 Extensive and Poor Metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 347-349. | 0.7 | 42 |
| 88 | Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats. <i>International Journal of Neuropsychopharmacology</i> , 1999, 2, 17-23. | 1.0 | 24 |
| 89 | Formulation and evaluation of a propanidid hydroxypropyl-β-cyclodextrin solution for intravenous anaesthesia. <i>International Journal of Pharmaceutics</i> , 1997, 159, 191-196. | 2.6 | 8 |
| 90 | Transplacental distribution of salbutamol enantiomers at Caesarian section. <i>British Journal of Clinical Pharmacology</i> , 1997, 44, 587-590. | 1.1 | 8 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 91 | Stability of an extemporaneously compounded levothyroxine sodium oral liquid. <i>American Journal of Health-System Pharmacy</i> , 1996, 53, 1157-1161. | 0.5 | 19 |
| 92 | Enantioselective disposition of albuterol in humans. <i>Clinical Reviews in Allergy and Immunology</i> , 1996, 14, 115-138. | 2.9 | 32 |
| 93 | Interaction of β_2 -adrenoceptor agonists with native cyclodextrins: Application to the development of chiral assays for terbutaline. <i>Pharmaceutica Acta Helvetiae</i> , 1996, 71, 293-296. | 1.2 | 2 |
| 94 | Stability of Hydrocortisone Oral Suspensions Prepared from Tablets and Powder. <i>Annals of Pharmacotherapy</i> , 1995, 29, 987-990. | 0.9 | 14 |